Inspired by the characteristics of platelets in immune thrombocytopenia that are easily phagocytosed by macrophages, this study designs and constructs anti‐CD41‐PLT‐VP16 for targeting abnormally activated macrophages in hemophagocytic lymphohistiocytosis (HLH). Here, ITGA2B is linked to hemophagocytic syndrome.